Ingenza – a world-leading contract research, development and manufacturing organisation (CRDMO) and technology accelerator – is delighted to announce its plans to relocate to the Moubray Building at Edinburgh Technopole, part of Pioneer Group. Following a detailed strategic review, the company has embarked on…
Ingenza is proud to announce that our molecular biology team recently co-authored a groundbreaking research paper published in Applied Microbiology International. The study addressed current challenges in producing recombinant proteins in the methylotrophic yeast Pichia pastoris. P. pastoris is a…
The entire team at Ingenza is sending heartfelt congratulations to our very own Dr Alison Arnold as she celebrates an amazing 20 years of working with us! Alison Arnold, PhD, joined Ingenza in 2003 as Senior Scientist for our fermentation…
Ingenza’s novel ester-impregnated pH strips significantly improve the accuracy of locating nasogastric (NG) feeding tubes in a study carried out in 10 NHS hospitals, as published in Diagnostic and Prognostic Research. The peer-reviewed paper found the innovative test to be…
At Ingenza, extraordinary accomplishments are a part of our everyday journey. We are thrilled to share the remarkable achievement of Scott Baxter, our Head of Downstream Processing, who recently completed the Courmayeur/Champex/Chamonix (CCC) race at Ultra-Trail du Mont-Blanc (UTMB). This…
Edinburgh-based Ingenza, a pioneer in engineering biology, is delighted to celebrate its 20 year anniversary this month. The milestone will be marked with an event on the 20th of April for esteemed colleagues and guests, providing an opportunity to reflect on the…
Edinburgh-based Ingenza, a pioneer in engineering biology, is pleased to announce the appointment of Dr Ian Shott CBE, FREng to the board as Executive Chairman. Ian joins Ingenza with over 35 years of experience in the global life science and biotechnology…
Jul 5, 2022 – The Coalition for Epidemic Preparedness Innovations (CEPI) has partnered with a consortium of research and technological institutions to develop a novel vaccine to provide protection against COVID-19 caused by current and future SARS-CoV-2 variants, as well as…
Biotechnology company Ingenza is delighted to announce that its recent partnership with Johnson Matthey has been selected to receive vital funding of £441,632.88 from the Department of Business, Energy and Industrial Strategy as part of the £1 billion fund from the…
Biotechnology company Ingenza is excited to report the successful conclusion to its recent six-month project with Johnson Matthey, a speciality chemicals and sustainable technologies supplier. Together, the companies have developed new, efficient approaches for the production of industrially-relevant enzymes –…